A. G. Dalgleish

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

A. Dalgleish, R. Chen, K. Dredge, 2002, British Journal of Cancer.

Thalidomide as an emerging immunotherapeutic agent.

G Muller, A. Dalgleish, A G Dalgleish, 1999, Immunology today.

Topical imiquimod and intralesional interleukin‐2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma

A. Dalgleish, M. Bodman-smith, D. Green, 2008, The British journal of dermatology.

Thalidomide analogue CC‐3052 reduces HIV+ neutrophil apoptosis in vitro

A. Dalgleish, I. Dransfield, M. Guckian, 2000, Clinical and experimental immunology.

Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity1

A. Dalgleish, S. Todryk, K. Dredge, 2002, The Journal of Immunology.

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.

K. O'Byrne, W. Steward, R. Sharma, 2006, European journal of cancer.

HTLV-1 infection in tropical spastic paraparesis: lymphocyte culture and serologic response.

R. Thorpe, A. Dalgleish, K. Cruickshank, 1988, AIDS research and human retroviruses.

Advances in human retroviruses.

A. Dalgleish, M. Malkovsky, A. G. Dalgleish, 1988, Advances in cancer research.